- biolinerx ( NASDAQ: BLRX ) is trading 9% lower as the company 's research and development costs and sales and marketing expenses rose.
- The company's Q2 loss of -$0.01 and beat estimates by $0.08.
- Sales and marketing expenses rose 250.9% Y/Y to $1.2M, primarily due to initiation of pre-commercialization activities related to Motixafortide, as well as an increase in market research.
- Research and development costs rose 5% to $5.4M, hurt by an increase in expenses associated with the AGI-134 study.
- Net financial expenses amounted to $0.3M, from $0.1M, a year earlier.
- The Company held $43.2M in cash.
For further details see:
BioLineRx falls 9% as costs increase in second quarter